EGFR and non-small cell lung carcinoma: As a result, numerous randomized controlled trails comparing the effectiveness of EGFR-TKIs in combination with anti-angiogenic medicines to EGFR-TKIs alone in the first-line therapy of advanced NSCLC with the EGFR mutation have been successfully completed globally.